catamaran

Catamaran, a large PBM, has issued its version of drug trend reporting, showing a per member per month trend of 2.4% in 2013 versus 2.6% in 2012.  Upward pressure is almost all from brand drug unit price increases and greater use and cost of specialty drugs, offset by continued generic expansion.  Catamaran is anticipating that trend could be as high as 5% in 2014, 6% in 2015 and 7.7% in 2016, driven by rising specialty use.